AR034150A1 - Empleo de exemestano y producto que contiene exemestano - Google Patents
Empleo de exemestano y producto que contiene exemestanoInfo
- Publication number
- AR034150A1 AR034150A1 ARP010104233A ARP010104233A AR034150A1 AR 034150 A1 AR034150 A1 AR 034150A1 AR P010104233 A ARP010104233 A AR P010104233A AR P010104233 A ARP010104233 A AR P010104233A AR 034150 A1 AR034150 A1 AR 034150A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- exemestane
- compound
- estrogen
- product containing
- Prior art date
Links
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 title abstract 5
- 229960000255 exemestane Drugs 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 3
- 229940011871 estrogen Drugs 0.000 abstract 3
- 239000000262 estrogen Substances 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- -1 retinoid compound Chemical class 0.000 abstract 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 abstract 2
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 abstract 2
- 102400000068 Angiostatin Human genes 0.000 abstract 2
- 108010079709 Angiostatins Proteins 0.000 abstract 2
- 102400001047 Endostatin Human genes 0.000 abstract 2
- 108010079505 Endostatins Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000004211 Platelet factor 4 Human genes 0.000 abstract 2
- 108090000778 Platelet factor 4 Proteins 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 229940123582 Telomerase inhibitor Drugs 0.000 abstract 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000002113 chemopreventative effect Effects 0.000 abstract 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940125798 integrin inhibitor Drugs 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 abstract 2
- 229960000460 razoxane Drugs 0.000 abstract 2
- 229960003522 roquinimex Drugs 0.000 abstract 2
- 230000003637 steroidlike Effects 0.000 abstract 2
- 239000003277 telomerase inhibitor Substances 0.000 abstract 2
- 229960003433 thalidomide Drugs 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 abstract 1
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 abstract 1
- 229940122558 EGFR antagonist Drugs 0.000 abstract 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 239000012627 chemopreventive agent Substances 0.000 abstract 1
- 229940124443 chemopreventive agent Drugs 0.000 abstract 1
- 229940121647 egfr inhibitor Drugs 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 abstract 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 abstract 1
- 239000002525 vasculotropin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Empleo inhibidor de la aromatasa, exemestano, ya sea solo o en combinación con otros agentes terapéuticos en la quimioprevención del cáncer estrógeno-dependiente en mamíferos, incluso seres humanos, de alto riesgo. Producto que contiene exemestano y otro agente terapéutico seleccionado entre un compuesto antiinflamatorio no esteroide (NSAID), un compuesto retinoide, un inhibidor de la farnesil-proteína transferasa, un inhibidor de la metaloproteasa de matriz, un inhibidor de la integrina avb3; un inhibidor de la proteincinasa, linomida, angiostatina, dehidroepiandrosterona (DHEA), un inhibidor de la telomerasa, plaqueta factor 4 (endostatina), arzoxifeno, indoxifeno, un inhibidor de la ciclooxigenasa, SU 5416, SU 6668, razoxin, fluvestrant, EM 800 y talidomida, o una mezcla de los mismos, como una preparación combinada para el empleo simultáneo, separado o sucesivo en el tratamiento del cáncer estrógeno-dependiente. Producto que contiene exemestano y otro agente quimiopreventivo seleccionado entre un compuesto de taxano, un compuesto antiinflamatorio no esteroide (NSAID), un compuesto retinoide, un inhibidor de la farnesil-proteína transferasa, un inhibidor de la metaloproteasa de matriz, un inhibidor de la integrina avb3, un compuesto de antraciclina, un anticuerpo contra HER2, e inhibidor o antagonista de EGFR, un inhibidor de la proteincinasa, linomida, angiostatina, un inhibidor de la ciclooxigenasa, razoxin, dehidroepiandrosterona (DHEA), un inhibidor de la telomerasa, plaqueta factor 4 (endostatina), un antiestrógeno, un inhibidor del VEGF y talidomida, o una mezcla de los mismos, como una preparación combinada para el empleo simultáneo, separado o sucesivo en la quimioprevención y control del crecimiento del cáncer estrógeno-dependiente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65805200A | 2000-09-08 | 2000-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034150A1 true AR034150A1 (es) | 2004-02-04 |
Family
ID=24639711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104233A AR034150A1 (es) | 2000-09-08 | 2001-09-06 | Empleo de exemestano y producto que contiene exemestano |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040024044A1 (es) |
| EP (1) | EP1317270A1 (es) |
| JP (1) | JP2004508334A (es) |
| KR (1) | KR20030043955A (es) |
| CN (1) | CN1729002A (es) |
| AR (1) | AR034150A1 (es) |
| AU (2) | AU8986501A (es) |
| BR (1) | BR0113625A (es) |
| CA (1) | CA2419590A1 (es) |
| MX (1) | MXPA03001983A (es) |
| MY (1) | MY137766A (es) |
| NZ (1) | NZ524104A (es) |
| PE (1) | PE20020348A1 (es) |
| WO (1) | WO2002020020A1 (es) |
| ZA (1) | ZA200301309B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040053900A1 (en) * | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
| GB0017635D0 (en) * | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
| US6903121B1 (en) * | 2000-08-17 | 2005-06-07 | Allergan, Inc. | Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| CA2436326C (en) * | 2001-01-09 | 2012-08-14 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| MXPA03006607A (es) * | 2001-01-26 | 2003-09-22 | Upjohn Co | Metodo combinado para tratar trastornos dependientes de hormonas. |
| DE10154464B4 (de) * | 2001-11-08 | 2005-10-20 | Max Delbrueck Centrum | Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol |
| US8318752B2 (en) | 2003-09-19 | 2012-11-27 | Astrazeneca Ab | 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same |
| CA2595395A1 (en) * | 2005-02-09 | 2006-08-17 | Genentech, Inc. | Inhibiting her2 shedding with matrix metalloprotease antagonists |
| EP1937251A2 (en) * | 2005-04-25 | 2008-07-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
| US8324194B2 (en) * | 2005-11-22 | 2012-12-04 | Incyte Corporation | Combination therapy for the treatment of cancer |
| BRPI0707655A2 (pt) * | 2006-02-14 | 2011-05-10 | Wyeth Corp | composiÇço farmacÊutica aquosa, mÉtodo para preparar uma composiÇço farmacÊutica, produto, mÉtodo para tratar um indivÍduo sofrendo de artrite ou endometriose, e, kit |
| BRPI0709410A2 (pt) * | 2006-03-20 | 2011-07-12 | Javelin Pharmaceuticals Inc | composição farmacêutica e método para tratar um mamìfero necessitando de um agente analgésico, anti-inflamatório ou um antipirético |
| KR20140038575A (ko) * | 2006-03-28 | 2014-03-28 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
| JP2009534462A (ja) * | 2006-04-24 | 2009-09-24 | パナセア バイオテック リミテッド | ニメスリドを含有する新規な低用量医薬組成物、その調製および使用 |
| CA2700664A1 (en) * | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists |
| CN101468023B (zh) * | 2007-12-26 | 2011-02-02 | 上海复星医药（集团）股份有限公司 | 依西美坦片及其制备工艺 |
| KR100925811B1 (ko) * | 2007-12-28 | 2009-11-06 | 주식회사 지에스메디칼 | 척추 고정기구 |
| EP2580210B1 (en) | 2010-06-10 | 2017-03-01 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| EA201300341A1 (ru) | 2010-09-16 | 2013-09-30 | Шимода Байотек (Пти) Лтд. | Композиция фулвестранта и способы применения |
| EP2791132A4 (en) | 2011-12-14 | 2015-08-05 | Seragon Pharmaceuticals Inc | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| RS64535B1 (sr) | 2013-09-24 | 2023-09-29 | Fujifilm Corp | Farmaceutska kompozicija jedinjenja koje sadrži azot ili njegovu so, ili njihov kompleks sa metalom |
| CN108779077A (zh) | 2015-12-30 | 2018-11-09 | 圣路易斯大学 | 作为pan整合素拮抗剂的间位氮杂环氨基苯甲酸衍生物 |
| TWI639430B (zh) * | 2016-08-27 | 2018-11-01 | 中國醫藥大學 | 醫藥組合物用於製備治療胃癌藥物的用途 |
| MX2022008392A (es) * | 2020-01-10 | 2022-08-08 | Takeda Pharmaceuticals Co | Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. |
| EP4493551A1 (en) | 2022-03-14 | 2025-01-22 | Slap Pharmaceuticals LLC | Multicyclic compounds |
| CN114948901B (zh) * | 2022-05-06 | 2023-04-21 | 郑州大学第一附属医院 | 一种协同治疗乳腺癌的依西美坦纳米粒、制剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8517360D0 (en) * | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
| AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| IL143901A0 (en) * | 1998-12-23 | 2002-04-21 | Searle & Co | Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia |
| GB9911582D0 (en) * | 1999-05-18 | 1999-07-21 | Pharmacia & Upjohn Spa | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
| GB0005257D0 (en) * | 2000-03-03 | 2000-04-26 | Pharmacia & Upjohn Spa | Breast cancer hormonal therapy |
-
2001
- 2001-08-31 AU AU8986501A patent/AU8986501A/xx active Pending
- 2001-08-31 JP JP2002524504A patent/JP2004508334A/ja not_active Withdrawn
- 2001-08-31 NZ NZ524104A patent/NZ524104A/xx unknown
- 2001-08-31 EP EP01969689A patent/EP1317270A1/en not_active Withdrawn
- 2001-08-31 CA CA002419590A patent/CA2419590A1/en not_active Abandoned
- 2001-08-31 WO PCT/EP2001/010172 patent/WO2002020020A1/en not_active Ceased
- 2001-08-31 KR KR10-2003-7003401A patent/KR20030043955A/ko not_active Ceased
- 2001-08-31 MX MXPA03001983A patent/MXPA03001983A/es not_active Application Discontinuation
- 2001-08-31 US US10/363,935 patent/US20040024044A1/en not_active Abandoned
- 2001-08-31 CN CNA018153038A patent/CN1729002A/zh active Pending
- 2001-08-31 AU AU2001289865A patent/AU2001289865B2/en not_active Ceased
- 2001-08-31 BR BR0113625-9A patent/BR0113625A/pt not_active Application Discontinuation
- 2001-09-05 PE PE2001000890A patent/PE20020348A1/es not_active Application Discontinuation
- 2001-09-05 MY MYPI20014168A patent/MY137766A/en unknown
- 2001-09-06 AR ARP010104233A patent/AR034150A1/es unknown
-
2003
- 2003-02-18 ZA ZA200301309A patent/ZA200301309B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20020348A1 (es) | 2002-04-18 |
| WO2002020020A1 (en) | 2002-03-14 |
| EP1317270A1 (en) | 2003-06-11 |
| NZ524104A (en) | 2004-12-24 |
| AU8986501A (en) | 2002-03-22 |
| AU2001289865B2 (en) | 2007-03-01 |
| BR0113625A (pt) | 2003-07-22 |
| MY137766A (en) | 2009-03-31 |
| ZA200301309B (en) | 2004-02-18 |
| MXPA03001983A (es) | 2003-06-24 |
| CA2419590A1 (en) | 2002-03-14 |
| JP2004508334A (ja) | 2004-03-18 |
| US20040024044A1 (en) | 2004-02-05 |
| KR20030043955A (ko) | 2003-06-02 |
| CN1729002A (zh) | 2006-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034150A1 (es) | Empleo de exemestano y producto que contiene exemestano | |
| AR034900A1 (es) | Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica | |
| ES2157307T3 (es) | Composicion topica que contiene un antagonista de sustancia p. | |
| PA8606201A1 (es) | DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| AR054566A1 (es) | Tratamientoombinado de los tumores que expresan el her | |
| AR046510A1 (es) | Composicion de un antagonista de vegf y un agente anti-proliferativo | |
| SV2003001493A (es) | Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion | |
| UY27533A1 (es) | Composiciones farmacéuticas que contienen oxibutinina | |
| AR020999A1 (es) | Composiciones y proceso para la elaboracion de isotretinoina | |
| GT200100175A (es) | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento. | |
| ECSP034869A (es) | Una composicion para la piel, permeable selectiva inhibidora de ciclooxigenasa-2 | |
| ES2185124T3 (es) | Composiciones de teñido de las fibras queratinicas que contienen derivados de indazoles de amina y procedimiento de teñido. | |
| CR7611A (es) | Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona | |
| MX2022009936A (es) | Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4). | |
| AR109263A2 (es) | Composición que comprende moxidectina | |
| AR032415A1 (es) | Producto para el modelado del cabello, de doble fase, que brinda beneficios de modelado y acondicionamiento | |
| AR034813A1 (es) | Composiciones farmaceuticas y uso de las mismas | |
| AR021370A1 (es) | Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| ES2190205T3 (es) | Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda. | |
| AR024998A1 (es) | Nuevos retinoides para el tratamiento del enfisema | |
| AR032872A1 (es) | Composicion para aclarar la piel y el metodo de aplicacion | |
| ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
| AR048050A1 (es) | Formas de administracion masticables, no comprimidas, dosificadas individualmente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |